Occam Places Bill Brondyk as CSO at Invetx
_430x344.jpg)
Invetx, an Anterra Capital investment, is building the world’s premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. In 2020, the company raised a $15M series A to advance Invetx’s pipeline of veterinary biologic drugs leveraging breakthroughs in human biopharma. Partnerships with AbCellera and WuXi Biologics followed shortly after. And in 2022, the company closed a $60M series B from F-Prime, Novo and Casdin.
But before all that, in September of 2019, Occam recruited Bill Brondyke to be the company's first CSO. Brondyke is seasoned drug hunter with 20+ years of experience in developing protein therapeutics for oncology indications, immune-mediated diseases, infectious diseases, rare diseases and reproductive health and contraception.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.